|
| HST Global, Inc., currently has the rights to a pre-clinical outcome-based study using the homeopathic remedy trade named “salicinium”. This natural substance, which is plant-derived, is both oral and a parenteral active inhibitor of certain fermenting enzyme dynamics in the cancer cells. Clinical studies demonstrate that salicinium alters malignant cell fermentation dynamics, blocks cell division (mitosis), and causes fermenting cancer cells to lose their ability to withstand innate immune reactions. |
|
